OneAscent Financial Services LLC Sells 1,231 Shares of Pfizer Inc. (NYSE:PFE)

OneAscent Financial Services LLC cut its holdings in Pfizer Inc. (NYSE:PFE) by 5.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 23,395 shares of the biopharmaceutical company’s stock after selling 1,231 shares during the period. OneAscent Financial Services LLC’s holdings in Pfizer were worth $649,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. VisionPoint Advisory Group LLC boosted its stake in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares during the last quarter. GoalVest Advisory LLC boosted its stake in Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares during the last quarter. Creekmur Asset Management LLC acquired a new position in Pfizer during the 4th quarter valued at about $32,000. Tennessee Valley Asset Management Partners acquired a new position in Pfizer during the 4th quarter valued at about $36,000. Finally, DiNuzzo Private Wealth Inc. acquired a new position in Pfizer during the 4th quarter valued at about $37,000. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Up 0.6 %

Pfizer stock opened at $27.98 on Friday. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $37.80. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The business’s 50 day simple moving average is $27.90 and its 200 day simple moving average is $27.68.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter in the prior year, the business earned $1.23 earnings per share. Pfizer’s revenue for the quarter was down 19.5% on a year-over-year basis. As a group, research analysts expect that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be issued a dividend of $0.42 per share. The ex-dividend date is Thursday, July 25th. This represents a $1.68 dividend on an annualized basis and a yield of 6.00%. Pfizer’s payout ratio is -2,799.53%.

Analyst Ratings Changes

PFE has been the subject of a number of analyst reports. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. BMO Capital Markets restated an “outperform” rating and issued a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Wednesday. Finally, Morgan Stanley boosted their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Nine investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $35.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.